Search Results

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company) today announced Walter Klemp, President and Chief Executive Officer of Moleculin will present at the MedInvest Biotech & Pharma Investor Conference behind held in New York City, NY on Thursday, April 4, 2024 at 4:10 PM ET.

Moleculin Biotech, Inc. announced that it will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Thursday, March 28, 2024 at 12:00 PM ET.

JTC Team (“JTC”), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor “What This Means” segment featuring Moleculin Biotech (NASDAQ:MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses.

Moleculin Biotech, Inc. announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 3:00 PM ET.

Moleculin Biotech, Inc. reported additional efficacy findings from the Company’s ongoing Phase 1B/2 clinical trial evaluating Annamycin in combination with Cytarabine for the treatment of subjects with acute myeloid leukemia.

Moleculin Biotech, Inc. today announced the formation of its Annamycin Scientific Advisory Board and inaugural appointment of Dr. Martin Tallman.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company) today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for U.S. Patent number 11,980,634 titled, “Method of Reconstituting Liposomal Annamycin” (the ‘634 patent’) to be issued on May 14, 2024 to Moleculin and The University of Texas System Board of Regents.

Moleculin Biotech, Inc. today announced Jonathan Foster, Executive VP and Chief Financial Officer of Moleculin will participate in a fireside chat at the 36th Annual ROTH Conference on March 18, 2024 at 9:00 AM PT.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the fiscal year ended December 31, 2023.

Moleculin Biotech, Inc. today announced that it will report its financial results for the quarter ended March 31, 2024, on Friday, May 10, 2024.